BioSpace News Archive

Agilent Technologies Inc. will release fourth quarter fiscal year 2019 financial results after the stock market closes on November 25.

In recognition of National Diabetes Month, Covetrus®, a global leader in animal-health technology and services, will donate $1 to The Pet Fund® for every order that includes a featured diabetes care product throughout November.

First-to-market functionality allows health plans and ACOs to automatically share actionable information about populations succinctly and in real-time with care teams across the Collective network

Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that management will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 10:20 a.m. Mountain Time.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced the publication of results from the Phase 3 studies, SAKURA 1 and SAKURA 2, in Plastic and Reconstructive Surgery (PRS), the peer reviewed Journal of the American Society of Plastic Surgeons.

Sharps Compliance Corp. (Nasdaq: SMED) announced today that David P. Tusa, Chief Executive Officer will attend the ROTH New Industrials & Technology Day to be held Wednesday, November 13, 2019 at the Lotte New York Palace Hotel.

BURLINGAME, Calif., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies with biomarker patient enrichment selection, today announced that it is hosting an investor and analyst event on Friday, November 8, 2019 from 6:00 – 7:30 pm ET, during the Society for Immunotherapy of Cancer (SITC) Annual Meeting in National Harbor, Maryland. The e

Company plans to release its third quarter 2019 financial results on Wednesday, November 13, 2019 after the market closes.

Mr. Meisner brings more than two decades of experience providing counsel to public and private companies across key legal and operational functions, including regulatory compliance, debt and equity financings, mergers and acquisitions, strategic partnerships and corporate governance.

The presentation will highlight AZTherapies’ lead Phase 3 clinical candidate ALZT-OP1 for the treatment of early Alzheimer’s disease and its pipeline of candidates targeting neuroinflammation to treat neurodegenerative diseases.